SELLAS Life Sciences Group (SLS) said Tuesday the US Food and Drug Administration has granted its Galinpeimut-S immunotherapy targeting Wilms Tumor-1 for treating pediatric acute myeloid leukemia Rare Pediatric Disease Designation.
The designation could potentially qualify SELLAS for a "Priority Review Voucher," if the therapy is approved for pediatric AML in the future, the company said.
Shares of the company rose 1.6% in early Tuesday trading.
Price: 1.27, Change: +0.02, Percent Change: +1.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。